Literature DB >> 25425580

Novel targets for the treatment of ameloblastoma.

K Heikinheimo1, K J Kurppa2, K Elenius3.   

Abstract

Entities:  

Keywords:  biological therapy; genetic markers; jaw neoplasms; mitogen-activated protein kinase kinases; mutation; odontogenic tumors

Mesh：

Substances：

Year:  2014        PMID： 25425580      PMCID： PMC4438731          DOI： 10.1177/0022034514560373

Source DB:  PubMed          Journal:  J Dent Res        ISSN： 0022-0345            Impact factor:   6.116


× No keyword cloud information.
  15 in total

1.  Early dental epithelial transcription factors distinguish ameloblastoma from keratocystic odontogenic tumor.

Authors:  K Heikinheimo; K J Kurppa; A Laiho; S Peltonen; A Berdal; A Bouattour; B Ruhin; J Catón; I Thesleff; I Leivo; P R Morgan
Journal:  J Dent Res       Date:  2014-11-14       Impact factor: 6.116

2.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Authors:  Anirudh Prahallad; Chong Sun; Sidong Huang; Federica Di Nicolantonio; Ramon Salazar; Davide Zecchin; Roderick L Beijersbergen; Alberto Bardelli; René Bernards
Journal:  Nature       Date:  2012-01-26       Impact factor: 49.962

3.  A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.

Authors:  Huaibin Chen; Jinghong Ma; Wanqing Li; Anna V Eliseenkova; Chongfeng Xu; Thomas A Neubert; W Todd Miller; Moosa Mohammadi
Journal:  Mol Cell       Date:  2007-09-07       Impact factor: 17.970

4.  The odontogenic keratocyst: a cyst, or a cystic neoplasm?

Authors:  T-J Li
Journal:  J Dent Res       Date:  2011-02       Impact factor: 6.116

5.  Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.

Authors:  James Kim; Blake T Aftab; Jean Y Tang; Daniel Kim; Alex H Lee; Melika Rezaee; Jynho Kim; Baozhi Chen; Emily M King; Alexandra Borodovsky; Gregory J Riggins; Ervin H Epstein; Philip A Beachy; Charles M Rudin
Journal:  Cancer Cell       Date:  2013-01-03       Impact factor: 31.743

6.  MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Authors:  Paolo A Ascierto; Dirk Schadendorf; Carola Berking; Sanjiv S Agarwala; Carla Ml van Herpen; Paola Queirolo; Christian U Blank; Axel Hauschild; J Thaddeus Beck; Annie St-Pierre; Faiz Niazi; Simon Wandel; Malte Peters; Angela Zubel; Reinhard Dummer
Journal:  Lancet Oncol       Date:  2013-02-13       Impact factor: 41.316

Review 7.  Cell signaling by receptor tyrosine kinases.

Authors:  Mark A Lemmon; Joseph Schlessinger
Journal:  Cell       Date:  2010-06-25       Impact factor: 41.582

8.  Activating FGFR2-RAS-BRAF mutations in ameloblastoma.

Authors:  Noah A Brown; Delphine Rolland; Jonathan B McHugh; Helmut C Weigelin; Lili Zhao; Megan S Lim; Kojo S J Elenitoba-Johnson; Bryan L Betz
Journal:  Clin Cancer Res       Date:  2014-07-03       Impact factor: 12.531

9.  FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.

Authors:  Sara A Byron; Michael Gartside; Matthew A Powell; Candice L Wellens; Feng Gao; David G Mutch; Paul J Goodfellow; Pamela M Pollock
Journal:  PLoS One       Date:  2012-02-23       Impact factor: 3.240

10.  High frequency of BRAF V600E mutations in ameloblastoma.

Authors:  Kari J Kurppa; Javier Catón; Peter R Morgan; Ari Ristimäki; Blandine Ruhin; Jari Kellokoski; Klaus Elenius; Kristiina Heikinheimo
Journal:  J Pathol       Date:  2014-01-31       Impact factor: 7.996
View more
  11 in total

1.  Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas.

Authors:  Alan Motta do Canto; Barbara Michaela Reis da Silva Marcelino; Juliana Lucena Schussel; Bruna F Wastner; Laurindo Moacir Sassi; Luciana Corrêa; Ronaldo Rodrigues de Freitas; Bengt Hasséus; Göran Kjeller; Celso Augusto Lemos Junior; Paulo Henrique Braz-Silva
Journal:  Clin Oral Investig       Date:  2018-05-31       Impact factor: 3.573

2.  Ameloblastoma: 25 Year Experience at a Single Institution.

Authors:  Tatyana Milman; Gui-Shuang Ying; Wei Pan; Virginia LiVolsi
Journal:  Head Neck Pathol       Date:  2016-06-07

3.  Molecular defects in BRAF wild-type ameloblastomas and craniopharyngiomas-differences in mutation profiles in epithelial-derived oropharyngeal neoplasms.

Authors:  Stephan Bartels; Akinyele Adisa; Timothy Aladelusi; Juliana Lemound; Angelika Stucki-Koch; Sami Hussein; Hans Kreipe; Christian Hartmann; Ulrich Lehmann; Kais Hussein
Journal:  Virchows Arch       Date:  2018-03-15       Impact factor: 4.064

4.  Ameloblastoma Phenotypes Reflected in Distinct Transcriptome Profiles.

Authors:  Shijia Hu; Joel Parker; Kimon Divaris; Ricardo Padilla; Valerie Murrah; John Timothy Wright
Journal:  Sci Rep       Date:  2016-08-05       Impact factor: 4.379

5.  Low frequency of BRAF V600E immunoexpression in mandibular ameloblastomas: An institutional study.

Authors:  Pankaj M Shirsat; Shivani Bansal; Pooja Prasad; Rajiv S Desai
Journal:  J Oral Maxillofac Pathol       Date:  2018 Sep-Dec

6.  The Expression of Selected Wnt Pathway Members (FZD6, AXIN2 and β-Catenin) in Canine Oral Squamous Cell Carcinoma and Acanthomatous Ameloblastoma.

Authors:  Barbora Putnová; Iveta Putnová; Miša Škorič; Marcela Buchtová
Journal:  Animals (Basel)       Date:  2021-05-29       Impact factor: 2.752

7.  MicroRNAs expression profile in solid and unicystic ameloblastomas.

Authors:  A Setién-Olarra; X Marichalar-Mendia; N G Bediaga; P Aguirre-Echebarria; J M Aguirre-Urizar; A Mosqueda-Taylor
Journal:  PLoS One       Date:  2017-10-20       Impact factor: 3.240

8.  The landscape of genetic alterations in ameloblastomas relates to clinical features.

Authors:  Sibel Elif Gültekin; Reem Aziz; Carina Heydt; Burcu Sengüven; Joachim Zöller; Ali Farid Safi; Matthias Kreppel; Reinhard Buettner
Journal:  Virchows Arch       Date:  2018-02-01       Impact factor: 4.064

9.  Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation.

Authors:  Gustavo S Fernandes; Daniel M Girardi; João Paulo G Bernardes; Felipe P Fonseca; Eduardo R Fregnani
Journal:  BMC Cancer       Date:  2018-09-12       Impact factor: 4.430

10.  Ameloblastomas Exhibit Stem Cell Potential, Possess Neurotrophic Properties, and Establish Connections with Trigeminal Neurons.

Authors:  Pierfrancesco Pagella; Javier Catón; Christian T Meisel; Thimios A Mitsiadis
Journal:  Cells       Date:  2020-03-06       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.